Beam Therapeutics Inc.
BEAM-302
alpha-1 antitrypsin deficiency
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews BEAM-302 for alpha-1 antitrypsin deficiency around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Beam shared that it has reached alignment with the FDA on a potential accelerated approval pathway for BEAM-302 based on AAT biomarkers evaluated over 12 months.”